NasVax seeks to provide its partners with access to current development programs via licensing and joint development arrangements, and to enable utilization of the technology platform for additional indications and applications that are not being explored internally by the company. NasVax also seeks access to novel vaccine antigens as well as targets for immunotherapy.
For partnering Contact Us.